Weight loss tech company Allurion is targeting the Central and Eastern Europe, Middle East, and Africa (CEMA) region after it entered a sales agency agreement with Medtronic for its artificial intelligence (AI)-powered weight loss programme.
The collaboration is another step in the close relationship between the US-based company and the medical device manufacturing giant. Medtronic is currently an investor in Allurion.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The weight loss programme includes a swallowable balloon combined with AI-powered remote monitoring software, called the Allurion Virtual Care Suite.
In a statement announcing the partnership, Allurion鈥檚 co-founder and CEO Shantanu Guar said Medtronic鈥檚 distribution channels will help offer the digital platform as a standalone product to help patients undergoing bariatric surgery.
A estimates that bariatric surgery devices across the EU5 market will be worth $21.4m by 2025.
According to Allurion, the device is the world鈥檚 first gastric balloon for weight loss that does not require a procedure for insertion, helps patients feel full, while the digital platform covers the analytics side of the treatment.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAllurion co-founder and CEO Shantanu Guar told 吃瓜黑料网 Network in February: 鈥淭he balloon helps you feel full, but the digital platform is keeping track of data and provides that link between patient and provider.鈥�
鈥淭he behaviour change programme then creates a cohesive experience that allows the patient to change their lifestyle 鈥� that鈥檚 what鈥檚 unique about our platform.鈥�
In February 2023, Allurion went public after signing a special purpose acquisition company (SPAC) deal with Compute Health.
